No Data
No Data
Rodman & Renshaw Maintains Unity Biotechnology(UBX.US) With Buy Rating, Cuts Target Price to $8
Express News | Rodman & Renshaw Initiates Coverage On Unity Biotechnology With Buy Rating, Announces Price Target of $8
UNITY Biotechnology to Participate in Upcoming Investor Conferences
UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know
Unity Biotechnology Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Buy Rating Reaffirmed for Unity Biotechnology Amid Promising Foselutoclax Trial Results and Strong Financial Position
No Data